Kerry MD - Terns Pharmaceuticals Chief Officer
| TERN Stock | USD 6.99 0.16 2.24% |
Insider
Kerry MD is Chief Officer of Terns Pharmaceuticals
| Address | 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 |
| Phone | 650 525 5535 |
| Web | https://www.ternspharma.com |
Terns Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2369) % which means that it has lost $0.2369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3473) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of June 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.42. At this time, Terns Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 11th of June 2024, Non Current Assets Total is likely to grow to about 1.4 M, while Total Assets are likely to drop about 170.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Janetta Trochimiuk | PDS Biotechnology Corp | 61 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| James MBA | Amylyx Pharmaceuticals | 57 | |
| MD MBA | Amylyx Pharmaceuticals | 63 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 |
Terns Pharmaceuticals Leadership Team
Elected by the shareholders, the Terns Pharmaceuticals' board of directors comprises two types of representatives: Terns Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Terns. The board's role is to monitor Terns Pharmaceuticals' management team and ensure that shareholders' interests are well served. Terns Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Terns Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weidong Zhong, CoFounder Officer | ||
| Jeffrey Jasper, Senior Research | ||
| Erin MD, President Development | ||
| Amy MBA, CEO Director | ||
| Seokho Esq, General COO | ||
| Mark Vignola, CFO Treasurer | ||
| Senthil Sundaram, CEO Director | ||
| Kerry MD, Chief Officer | ||
| Emil MD, Chief Oncology | ||
| Diana Chung, Senior Officer |
Terns Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Terns Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 222.21 M | ||||
| Shares Outstanding | 64.68 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 98.30 % | ||||
| Number Of Shares Shorted | 2.23 M | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Terns Stock
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.035 | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.